would agree that diagnosis is important in that it should lead to suitable management, treatment and some indication as to prognosis, However, I feel that subdividing dyslexias into primary and secondary has tended to make diagnosis more difficult and to confuse the matter further. Although it is quite understood that there are these two distinctions -in that primary dyslexia is genetically determined and typically has a familial incidence, and secondary dyslexia is usually the result of minimal brain dysfunction -the two conditions are not easily separated, since congenital only means existing at or present from birth and could well be due to an inherited condition or to some cerebral trauma, either in utero or during birth. I cannot agree with Dr Macdonald Critchley that his definition of primary dyslexia does not include speech and language delay, poor coordination, left/right confusion, occasional difficulties with arithmetic, severe difficulties in spelling and possible problems in constructional tasks, which is Michael Rutter's definition of specific reading retardation, since all the above are often present in developmental dyslexia, whatever the aetiology.
A further dimension in differential diagnosis has been added recently, in that many psychologists now talk not only about primary and secondary dyslexia, but also about deep dyslexia. It seems inappropriate to try to make differential diagnoses between these various dyslexias when what is really needed is treatment, and an accepted method has been developed over the last 40 years, culled from America, Australia, France and Denmark, which is indisputably effective in the vast majority of cases of specific reading, spelling and writing difficulties. (Li et al. 1956 , Burkitt 1967 ,combination chemotherapy in acute lymphoblastic leukaemia in children (Freireich et al. 1964) , MOPP scheme in Hodgkin's disease (De Vita & Serpick 1967) , COP scheme in non-Hodgkin's lymphoma, '5-day 5-drug' regimen in carcinoma of the breast (Cooper 1969) ,were all products of nonrandomized clinical trials. No one ever thought to compare the results of these schemes with a group of patients treated only with placebo. It is apparent that when cancer chemotherapy is really effective, randomized clinical trials are not necessary.
Why then do we need randomized clinical trials? It seems that clinical trials are useful -or even necessary -in order to demonstrate the degree of ineffectivenessof a new drug or a new combination scheme; or -to put it another way -clinical trials can prove that a new drug or a new combination scheme has a 'minimal' or at best a 'moderate' effectiveness, thus justifying the routine application in practice of this new mode of treatment. No randomized clinical trials ever proved that a new drug or a new scheme was really, dramatically effective. Clinical trials are also useful for testing a new scheme when the classical effective chemotherapy is no longer effective, for example ABVD when Hodgkin's disease becomes resistant to MOPP (Bonadonna et al. 1975) . Finally, randomized clinical trials raise conceptually-scientific clinical research above the muddle of empiricism. But can we compare the impact in clinical medicine of the modest results of randomized clinical trials, such as combination chemotherapy in carcinoma of the bowel, or even adjuvant chemotherapy in carcinoma of the breast, with the impressive breakthroughs of some nonrandomized clinical trials such as methotrexate in choriocarcinoma, MOPP in Hodgkin's disease, etc.?
The productivity of randomized clinical trials is only modest. This productivity must be compared
